Elicio Therapeutics (ELTX) Operating Margin (2020 - 2022)

Elicio Therapeutics has reported Operating Margin for 3 years, with the latest figure at 954.36% in Q2 2022.

• For the quarter ending Q2 2022, Operating Margin rose 242415.0% year-over-year to 954.36%; the trailing twelve-month figure through Mar 2023 stood at 3946.09% (down 382848.0% YoY), and the FY2022 full-year result was 1031.42%, down 88852.0% from the prior year.
• Operating Margin for Q2 2022 stood at 954.36%, down from 878.94% in the prior quarter.
• The five-year high for Operating Margin was 621.63% in Q4 2020, with the low at 5374.39% in Q1 2021.
• Historically, Operating Margin has averaged 1639.49% across 3 years, with a median of 1079.32% in 2021.
• Annual changes were most pronounced in 2021 — Operating Margin sank 100966 bps — and 2022, when it jumped 449545 bps.
• Elicio Therapeutics' Operating Margin stood at 621.63% in 2020, then tumbled by 91 bps to 58.22% in 2021, then sank by 1739 bps to 954.36% in 2022.
• The last three Operating Margin figures came in at 954.36% (Q2 2022), 878.94% (Q1 2022), and 58.22% (Q4 2021), per Business Quant data.